Generic Of Combination Hormone Therapy Patch Approved For Women

TL;DR

For listenersOffer from Amazon

Turn your wind-down time into listening time

• Thousands of audiobooks, podcasts and originals
• Listen on your phone, tablet or Echo — also offline
• Cancel anytime

Try Audible free →Free trial for new members

As an affiliate, we earn on qualifying purchases.Hide

The FDA approved the first generic version of a once-weekly estradiol-levonorgestrel patch for moderate to severe menopausal hot flashes and prevention of osteoporosis. It is indicated for postmenopausal women with an intact uterus, and its labeling retains significant contraindications, adverse effects and a boxed warning.

The U.S. Food and Drug Administration approved the first generic of a once-weekly estradiol-levonorgestrel patch for treating moderate to severe vasomotor symptoms and preventing osteoporosis in certain postmenopausal women. The patch, a generic version of Climara Pro, is indicated for women with an intact uterus, according to a report published October 20.

The transdermal system supplies 0.045 mg of estradiol and 0.015 mg of levonorgestrel daily while being replaced weekly. Estradiol is an estrogen; levonorgestrel is a progestogen. The FDA said the progestogen is included to reduce the risk of endometrial hyperplasia, an overgrowth of the uterine lining that can occur with estrogen use alone.

FDA Center for Drug Evaluation and Research director Michael Davis said in an agency statement that weekly dosing may help patients manage treatment. He described a patch as an alternative to daily oral medication that may help patients stay on track. The approval announcement does not establish how individual patients will respond or whether the generic will be available at a particular price.

The source report lists application-site reactions, vaginal bleeding, upper respiratory infection, breast, back or general pain, depression, headache and flu-like syndrome among adverse events reported in at least 5% of users. The labeling also lists conditions that rule out use, including undiagnosed abnormal genital bleeding, known or suspected breast cancer, certain estrogen-dependent cancers, active blood clots, liver impairment and some clotting disorders.

A Weekly Option With Key Safety Limits

The approval adds a generic option to a treatment category used for menopausal symptoms and osteoporosis prevention. A weekly patch may offer a different dosing routine from daily pills, though the FDA official’s statement that this could help patients stay on treatment is a potential benefit, not evidence that adherence or outcomes will improve for every user.

The product is not suitable for everyone. Its intact-uterus indication and listed contraindications mean eligibility depends on a patient’s medical history and the product’s prescribing information. Patients considering hormone therapy should discuss its potential benefits and risks with a qualified health professional; this approval does not change those individual treatment decisions.

How the Combination Patch Works

The patch combines estradiol with levonorgestrel and is applied to the skin once a week. The reported indications are relief of moderate to severe vasomotor symptoms—such as hot flashes—and prevention of osteoporosis in postmenopausal women who have not had a hysterectomy. The agency’s rationale for including a progestogen is to reduce the risk of endometrial changes associated with estrogen alone.

The report places the approval amid recent endorsements from the American College of Obstetricians and Gynecologists and the American College of Physicians for treatment of menopausal symptoms. It also says the FDA recently announced plans to remove boxed warnings from a number of hormone therapy products. However, the report states that this patch’s prescribing information still carries a boxed warning; the plans described do not amount to confirmation that this product’s warning has been changed.

“Once-weekly dosing can make a real difference in how patients manage their care.”

— Michael Davis, director of the FDA’s Center for Drug Evaluation and Research

Availability and Warning Changes Remain Unclear

The source report does not identify the generic’s manufacturer, its launch date, expected price, or whether it will be available immediately. It also does not provide comparative data on cost, effectiveness or adherence against the branded patch or other hormone therapy options.

The report says FDA plans to remove boxed warnings from a number of menopausal hormone therapy products, but does not specify whether or when this patch’s warning will change. For now, the reported prescribing information includes a boxed warning based on findings from the Women’s Health Initiative concerning cardiovascular disorders, probable dementia, breast cancer and endometrial cancer. The report does not supply updated risk estimates or further detail on the agency’s planned labeling changes.

Watch for Label and Market Details

Further developments to watch include the generic’s manufacturer, market availability and pricing, as well as any FDA updates to the product’s labeling. Until those details are reported, the approval confirms that a generic version has been authorized, but not when patients can obtain it or at what cost.

People weighing this treatment can ask a qualified health professional whether its indication and safety profile fit their circumstances. The FDA approval does not remove the contraindications or establish that the patch is appropriate for a particular patient.

Key Questions

What did the FDA approve?

The FDA approved the first generic version of the once-weekly estradiol-levonorgestrel transdermal system, branded as Climara Pro.

Who is the patch indicated for?

It is indicated for postmenopausal women with an intact uterus to treat moderate to severe vasomotor symptoms and prevent osteoporosis. A qualified health professional can advise whether it is appropriate for an individual.

How often is the patch used?

The system is designed for once-weekly use and delivers daily doses of 0.045 mg estradiol and 0.015 mg levonorgestrel, according to the report.

What safety information does the report mention?

Reported adverse events include application-site reactions and vaginal bleeding, among others. The labeling also lists contraindications and a boxed warning; patients should consult a qualified health professional about the full prescribing information and their personal risks.

When will the generic be available, and what will it cost?

The source report does not give a launch date, manufacturer or price. Those details remain unclear.

Source: rss